$0.78
-0.08 (-9.54%)
Open$0.84
Previous Close$0.86
Day High$0.84
Day Low$0.77
52W High$2.38
52W Low$0.53
Volume—
Avg Volume248.2K
Market Cap41.90M
P/E Ratio—
EPS$-1.62
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+5,063.9% upside
Current
$0.78
$0.78
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.32M | 5.14M | 4.74M |
| Net Income | -86,737,669 | 951.6K | 665.5K |
| Profit Margin | -3,740.9% | 18.5% | 14.0% |
| EBITDA | -86,988,187 | 1.31M | 1.24M |
| Free Cash Flow | — | 380.5K | 530.0K |
| Rev Growth | — | -9.9% | +8.5% |
| Debt/Equity | 0.36 | 0.11 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |